IDEAYA lays out 2026 goals: darovasertib PFS data Q1, three Phase 3 trials, IDE849 registrational start

IDEAYA Biosciences, Inc.

Topline PFS results from Phase 2/3 OptimUM-02 for darovasertib+crizotinib in 1L HLA*A2-negative mUM expected Q1 2026.
Darovasertib to be in three randomized Phase 3 trials (OptimUM-02, -10, -11) across UM stages by H1 2026.
IDE849 (DLL3 TOP1 ADC) registrational monotherapy study in SCLC/NEC targeted to start by end of 2026.
IDE034 (B7H3/PTK7 ADC) Phase 1 dose escalation to begin Q1 2026; IDE892 (PRMT5) Phase 1 in Q1 2026.
Cash of $1.1 billion as of Sep 30, 2025, expected to fund operations into 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.